1. Characteristics and outcomes of autologous hematopoietic stem cell transplant recipients admitted to intensive care units: A multicenter study.
- Author
-
Nassar AP Jr, Archanjo LVF, Ranzani OT, Zampieri FG, Salluh JIF, Cavalcanti GFR, Moreira CEN, Viana WN, Costa R, Melo UO, Roderjan CN, Correa TD, de Almeida SLS, Azevedo LCP, Maia MO, Cravo VS, Bozza FA, Caruso P, and Soares M
- Subjects
- Critical Illness, Humans, Intensive Care Units, Retrospective Studies, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation
- Abstract
Purpose: Studies of critically ill hematopoietic stem cell transplantation (HSCT) recipients have mainly been single-center and focused on allogenic HSCT recipients. We aimed to describe a cohort of autologous HSCT with an unplanned intensive care unit (ICU) admission., Methods: This study is a retrospective cohort study of autologous HSCT performed as a treatment for a hematological malignancy, during their first unplanned ICU admission in 50 hospitals in Brazil. We assessed the hospital mortality and the association between mechanical ventilation, vasopressors, and renal replacement therapy and hospital mortality in autologous HSCT recipients, adjusted for potential confounders., Results: We included 301 patients. Multiple myeloma was the most common malignancy driving to HSCT. ICU and hospital mortality were 22.9% and 37.5%, respectively. After adjustment for potential confounders, mechanical ventilation (OR = 9.10; CI 95%, 4.82-17.15) was associated with hospital mortality, but vasopressors (OR = 1.43; CI 95%, 0.77-2.64) and renal replacement therapy (OR = 1.30; CI 95%, 0.63-2.66) were not., Conclusions: In this large cohort of critically ill autologous HSCT recipients, mechanical ventilation was the only organ support-therapy associated with increased mortality in autologous HSCT recipients., Competing Interests: Declaration of Competing Interest MS is founder of Epimed Monitor®, an electronic healthcare system used to collect data and track ICU quality metrics. FGZ has received grants for investigator-initiated studies from Ionis Pharmaceuticals (USA), Bactiguard (Sweden) and Brazilian Ministry of Health, none related to the scope of this study., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF